Case report

**Association between isotretinoin use and central retinal vein occlusion in an adolescent with minor predisposition for thrombotic incidents: a case report**

Georgios Labiris*1, Andreas Katsanos1, Maria Karapetsa2, Ioanna Mpanaka2 and Dimitrios Chatzoulis1

Address: 1Ophthalmology Department, University Hospital of Larissa, 41110 Larissa, Greece and 2Internal Medicine Department, University Hospital of Larissa, 41110 Larissa, Greece

Email: Georgios Labiris* - labiris@usa.net; Andreas Katsanos - andreakatbp@hotmail.com; Maria Karapetsa - mkarapetsa@gmail.gr; Ioanna Mpanaka - impanaka@yahoo.gr; Dimitrios Chatzoulis - d.chatzoulis@med.uth.gr

* Corresponding author

Abstract

**Introduction:** We report an adolescent boy with minimal pre-existing risk for thromboses who suffered central retinal vein occlusion associated with isotretinoin use for acne. To the best of our knowledge, this is the first well documented case of this association.

**Case presentation:** An otherwise healthy 17-year-old white man who was treated with systemic isotretinoin for recalcitrant acne was referred with central retinal vein occlusion in one eye. Although a detailed investigation was negative, DNA testing revealed that the patient was a heterozygous carrier of the G20210A mutation of the prothrombin gene. Despite the fact that this particular mutation is thought to represent only a minor risk factor for thromboses, it is probable that isotretinoin treatment greatly increased the risk of a vaso-occlusive incident in this patient.

**Conclusion:** Isotretinoin use may be associated with sight- and life-threatening thrombotic adverse effects even in young patients with otherwise minimal thrombophilic risk. Physicians should be aware of such potential dangers.

**Introduction**

Isotretinoin, a vitamin A derivative, is a synthetic retinoid used for the treatment of severe cystic acne that does not respond to other therapies. The drug appears to act by inhibiting sebaceous gland size and function. Besides being teratogenic, a number of adverse effects have been described for isotretinoin [1-3]. The most common ones include dryness and itching of the skin and mucous membranes. Less commonly reported adverse effects are headache, inflammatory bowel disease, anorexia, alopecia, pseudotumour cerebri, muscle and joint pains, as well as premature closure of epiphyseal growth plates in children's joints. An increase in serum lipid levels is also frequently seen [4]. Previous reports have indicated an association between isotretinoin use and thrombotic, thromboembolic or haemorrhagic events whereas the Canadian Adverse Reaction Newsletter described 11 such cases of thromboembolic incidents, strokes and myocardial infarctions for the period 1983–2005 [1-3].
Case presentation
A 17-year-old white man was referred by his ophthalmologist to the University Department of Ophthalmology in Larissa, Greece, with the diagnosis of central retinal vein occlusion (CRVO) in his left eye. The patient's ophthalmic history was negative, whereas his general medical history was only significant for acne, for which he had been treated with oral isotretinoin 20 mg three times daily (13-cis-retinoic acid, Accutane®) for the previous 6 weeks. He denied smoking, alcohol consumption and illicit substance use. The patient successfully participated in all regular sports activities at school, and presented a normal body mass index of 23.77. Besides cheilitis with dry, cracked and crusted lips, his initial physical examination was negative.

His uncorrected visual acuity was 12/10 in each eye and the intraocular pressure in his right and left eye was 14 and 17 mmHg, respectively. Funduscopy revealed optic disc oedema with retinal haemorrhages and engorged, tortuous veins in the left eye (Figure 1). His right eye had a normal fundus with an optic nerve head having a cup-to-disc ratio of 0.4. Visual fields examination revealed a superior arcuate scotoma in his left eye (Figure 2).

A detailed clinical investigation of all systems, including cardiovascular and neurological assessment was unremarkable. Total blood count with differential, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and routine laboratory testing were within normal ranges, except for a mild increase in low-density lipoprotein (LDL) cholesterol that was attributed to isotretinoin use. Urine analysis and 24-hour urine selection specimens were within normal ranges. Moreover, no viral or other systemic or localised infection was detected. Further investigation with plasma protein electrophoresis, autoimmune and tumour markers, screening for antiphospholipid syndrome, and cryoglobulinaemia was also negative. Finally, the patient presented normal values of protein C, protein S, antithrombin, and homocysteine. DNA testing for potential genetic thrombophilic predisposition revealed that the patient was a heterozygous carrier of the G20210A mutation of the prothrombin gene (Table 1). However, his family history was negative for thrombotic incidents even for senior relatives (grandparents). On the other hand, chest computed tomography (CT), abdominal ultrasound, brain and orbit magnetic resonance imaging (MRI) scans, as well as brain and orbit magnetic resonance angiography (MRA), were all negative.

Isotretinoin treatment was discontinued and the patient was initially given low molecular weight heparin, followed by oral anticoagulants (acenocoumarol, Sintrom®). Based on the notion that elevated intraocular pressure may be a risk factor for CRVO, intraocular pressure lowering medication was administered (brimonidine BID, Alphagan®). Due to the patient's slow response to the treatment, systemic steroids were added to the therapeutic scheme (methylprednisolone sodium acetate 500 mg intravenously for 3 days, then oral methylprednisolone 24 mg once daily for 1 month with gradual dosage decrease). Six months after the CRVO, the optic disc oedema had regressed and the haemorrhages had been absorbed. The patient's visual acuity remains 12/10 without signs of posterior- or anterior segment neovascularisation, whereas the visual field defect has slightly decreased in depth. Cheilitis was attributed to isotretinoin and resolved gradually after its discontinuation.

Discussion
Regarding the ocular adverse effects related to isotretinoin [5,6], they can be categorised into the following classes according to the World Health Organization classification for causality of suspected drug-related events: "certain", "probable/likely", "possible", "unlikely", "conditional/unclassified" and "inaccessible/unclassifiable". Thus, the "certain" category includes abnormal meibomian gland secretion and atrophy, intracranial hypertension with optic disc oedema, ocular sicca, corneal opacities, keratitis, myopia and decreased dark adaptation. The "probable/likely" category includes reversible decreased colour vision and permanent loss of dark adaptation. Adverse events that have a "possible" association with isotretinoin are permanent sicca, corneal ulcers, diplopia and eyelid oedema. The "unlikely" category is comprised of entities such as exophthalmos, keratoconus, glaucoma, activation of herpes simplex and pupil abnormalities. The "conditional/unclassified" and "inaccessible/unclassifiable" cat-

![Figure 1](https://example.com/fundusophthalmus.jpg)

**Figure 1**
Funduscopic image of the left eye. Fundus photograph of the patient's left eye with optic disc oedema, retinal haemorrhages and engorged, tortuous veins. Photograph taken on the day of presentation.
Figure 2
Visual field of the left eye. Printout of the visual field test of the patient's left eye exhibiting a superior arcuate scotoma. Test performed 2 days after presentation.
isotretinoin intake and CRVO. The risk of thrombotic
Although the occurrence of this sight-threatening adverse
only had a minor genetic predisposition for thrombosis.
Oral isotretinoin treatment was associated with central
coagulation process by a still unexplained mechanism.
Regarding the patient presented in this report, although
the MTHFR C677T mutation is not associated with a
thrombotic diathesis, heterozygosity in the G20210A
mutation is considered to be a minor predisposing factor
for thrombotic incidents in otherwise healthy young
adults. However, the introduction of isotretinoin treat-
ment possibly initiated or facilitated the thrombotic pro-
cess. Besides previous reports that indicated an association
between isotretinoin use and thrombotic, thromboemb-
olic or haemorrhagic events [1,2], the Canadian Adverse
Reaction Newsletter described 11 such cases of throm-
boembolic incidents, strokes and myocardial infarctions
for the period 1983–2005 [3]. Nine of the patients were
aged 29 or younger, whereas four of the 11 patients had
no other risk factor. Paradoxically, some reports indicate
a possible protective effect of isotretinoin in thromboemb-
olic disorders. Some of the underlying mechanisms may
be the decrease in lipoprotein (a) which has been impli-
cated in coronary heart disease and stroke and the inhibi-
tion of vascular smooth muscle proliferation and vessel
remodelling [9,10]. Thus, the drug appears to act on the
coaulation process by a still unexplained mechanism.

Considering our patient, the relationship between
isotretinoin intake and CRVO is "probable" both accord-
ing to the Naranjo probability scale [11] and the World
Health Organization classification for causality of drug-
related reactions.

**Conclusion**

Oral isotretinoin treatment was associated with central
retinal vein occlusion in our adolescent male patient who
only had a minor genetic predisposition for thrombosis.
Although the occurrence of this sight-threatening adverse
event is rare, there is a probable relationship between
isotretinoin intake and CRVO. The risk of thrombotic

| Table 1: DNA testing for genetic predisposition to hypercoagulability states |
|---------------------------------|-------------------------------|
| **Mutation tested**            | **Result**                    |
| FII G20210A                    | Heterozygous G->A             |
| FV G1691A                      | Normal                        |
| MTHFR C677T                    | Heterozygous C->T             |
| MTHFR A1298C                   | Normal                        |
| PAI-1 (-675 & -844)            | Normal                        |

**Consent**

Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**

GL was involved in the ophthalmic management of the
patient and contributed to writing the manuscript. AK per-
formed some of the ophthalmic examinations and was
involved in writing and reviewing the manuscript. MK car-
rried out part of the general medical work-up and the
genetics investigation. IM performed the general clinical
investigation. DC was involved in writing and reviewing the manuscript. MK car-
ried out part of the general medical work-up and the

**Acknowledgements**

This report involved no sources of funding for any of the authors.

**References**

1. Moeller KE, Touma SC: Prolonged thrombocytopenia associ-
ated with isotretinoin. Ann Pharmacother 2003, 37:1622-1624.
2. Laroche ML, Meslan-Montoro F, Merle L, Vallat JP: Cerebral
ischemia probably related to isotretinoin. Ann Pharmacother
2007, 41:1073-1076.
3. Springuel P, Roy G: Isotretinoin (Accutane): myocardial infarc-
tion, cerebrovascular and thromboembolic disorders. Can
Adverse React Newslett 2006, 16(3):3.
4. Zane LT, Layden WA, Marqualing AL, Manos MM: A population-
based analysis of laboratory abnormalities during isotretin-
oin therapy for acne vulgaris. Arch Dermatol 2006,
142:1016-1022.
5. Fraunfelder FT, Fraunfelder FW, Edwards R: Ocular side effects
possibly associated with isotretinoin usage. Am J Ophthalmol
2001, 132:299-305.
6. Fraunfelder FW, Fraunfelder FT: Adverse ocular drug reactions
recently identified by the national registry of drug-induced
ocular side effects. Ophthalmology 2004, 111:1275-1279.
7. Santodomingo-Rubido J, Barrado-Navascues E, Rubidoo-Crespo M-J:
Drug-induced side effects with isotretinoin. Ophthalmic Physiol
Opt 2008, 28:497-501.
8. Miles S, McGlathery W, Abernathie B: The importance of screen-
ing for laser assisted in situ keratomileusis operation
(LASIK) before prescribing isotretinoin. J Am Acad Dermatol
2006, 54:180-181.
9. Georgala S, Schulpis KH, Poutouridou I, Papadogergaki H: Effects of
isotretinoin therapy on lipoprotein (a) serum levels. Int J Der-
matol 1997, 36:863-864.
prevents vessel remodelling following arterial injury. Cardiovasc Surg 1997, 7:633-639.

11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.